Intravenous Glutathione Administration Protocol
No evidence-based, FDA-approved intravenous (IV) glutathione protocol exists that specifies dose, dilution, infusion rate, and frequency for a defined indication. [1], [2]
Regulatory Status
Reduced L-glutathione for injection is not an FDA-approved drug product for any condition, including injection and inhalation. [2]
Recommended Dose, Dilution, and Infusion Rate
An IV glutathione dose-ranging protocol with specific dilution and infusion rate instructions is not established in FDA-approved labeling. [1], [2]
Frequency of Administration
A frequency of administration for IV glutathione is not established in FDA-approved labeling. [1], [2]
Monitoring During IV Administration
Acute monitoring for infusion-related reactions is recommended, given reported symptoms consistent with exposure to excessive bacterial endotoxin (for example, fever, chills, myalgia, headache, nausea, vomiting, and hypotension). [1]
- Vital signs monitoring for hypotension and fever is recommended during administration. [1]
- Immediate reassessment and discontinuation are recommended if systemic reaction symptoms occur, including dyspnea and hypotension. [1]
Contraindications and When to Withhold Therapy
Absolute contraindications specific to IV glutathione are not provided in FDA-approved labeling because reduced L-glutathione injection is not FDA-approved. [2]
Withholding decisions should rely on patient safety principles for unapproved compounded sterile injectables, particularly when product quality may not meet sterile and endotoxin safety expectations. [1], [3]
Documented safety concerns include systemic reactions temporally associated with IV administration of compounded L-glutathione in association with potentially excessive endotoxin levels. [1]
Safety-Directed Practical Guardrails
Sterile-compounding risk must be treated as a primary safety determinant, since inappropriate ingredient sourcing and endotoxin limits can produce severe systemic reactions. [1]
If an IV glutathione product is being considered, only products manufactured and tested under appropriate sterile and endotoxin controls should be used, because testing alone does not ensure drug quality without appropriate production specifications for the IV route. [1]
Adverse Reaction Pattern Used for Triage
Reported adverse events after IV compounded L-glutathione include nausea, vomiting, lightheadedness, chills, body aches, sneezing, low blood pressure, difficulty breathing, and hospitalization. [1]
Reported episodes were consistent with reactions to excessive endotoxin exposure. [1]
Immediate Management of Suspected Reaction
Infusion interruption and escalation of care are recommended when severe infusion reactions occur, including hypotension, dyspnea, fever with shaking, or suspected bloodstream infection. [1]
Medication discontinuation is recommended when systemic symptoms progress or hemodynamic instability develops. [1]